4 results
To evaluate the effect of intranasal esketamine 84 mg on cognition, and duration of cognitive effects (if present), as assessed using a computerized test battery (Cogstate®).
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.
The primary objective is to investigate whether pharmacological conditioning with S(+)-ketamine compared to pharmacological conditioning with placebo medication reduces pain sensitivity in patients with FMS.
This study compares the efficacy of tafasitamab + lenalidomide + rituximab to the efficacy of placebo + lenalidomide + rituximab in terms of progression-free survival (PFS) in participants with R/R follicular lymphoma. In addition, the efficacy of…